BridgeBio Pharma, Inc. Stock-Based Compensation
BridgeBio Pharma, Inc. (BBIO) reported Stock-Based Compensation of $77.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- BridgeBio Pharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $44.07M, a 18.34% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $33.24M, a 28.44% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $34.64M, a 14.98% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $35.26M, a 29.82% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $133.02M, a 38.86% increase from fiscal 2024.
- BridgeBio Pharma, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $95.80M, a 11.88% decline from fiscal 2023.
- BridgeBio Pharma, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $108.71M, a 18.73% increase from fiscal 2022.
- BridgeBio Pharma, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $91.56M, a 7.99% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $77.31M 10-Q · filed 2026-08-10 | $111.95M derived: sum of 3 quarters · filed 2026-08-10 | $147.22M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $33.24M 10-Q · filed 2026-05-07 | $67.88M derived: sum of 2 quarters · filed 2026-05-07 | $103.14M derived: sum of 3 quarters · filed 2026-05-07 | $140.38M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $34.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $69.90M derived: sum of 2 quarters · filed 2026-02-24 | $107.14M derived: sum of 3 quarters · filed 2026-08-10 | $133.02M 10-K · filed 2026-02-24 |
| 2025-09-30 | $35.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $72.50M derived: sum of 2 quarters · filed 2026-08-10 | $98.39M 10-Q · filed 2025-10-29 | $128.51M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $37.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $63.12M 10-Q · filed 2026-08-10 | $93.25M derived: sum of 3 quarters · filed 2026-08-10 | $120.41M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $25.88M 10-Q · filed 2026-05-07 | $56.01M derived: sum of 2 quarters · filed 2026-05-07 | $83.17M derived: sum of 3 quarters · filed 2026-05-07 | $104.63M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $30.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $57.29M derived: sum of 2 quarters · filed 2026-02-24 | $78.74M derived: sum of 3 quarters · filed 2026-02-24 | $95.80M 10-K · filed 2026-02-24 |
| 2024-09-30 | $27.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $48.62M derived: sum of 2 quarters · filed 2025-10-29 | $65.67M 10-Q · filed 2025-10-29 | $102.70M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $21.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $38.51M 10-Q · filed 2025-08-05 | $75.54M derived: sum of 3 quarters · filed 2026-02-24 | $98.14M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $17.06M 10-Q · filed 2025-04-29 | $54.08M derived: sum of 2 quarters · filed 2026-02-24 | $76.68M derived: sum of 3 quarters · filed 2026-02-24 | $103.86M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $37.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $59.63M derived: sum of 2 quarters · filed 2026-02-24 | $86.80M derived: sum of 3 quarters · filed 2026-02-24 | $108.71M 10-K · filed 2026-02-24 |
| 2023-09-30 | $22.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $49.78M derived: sum of 2 quarters · filed 2024-11-12 | $71.69M 10-Q · filed 2024-11-12 | $93.47M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $27.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $49.09M 10-Q · filed 2024-08-01 | $70.87M derived: sum of 3 quarters · filed 2025-02-20 | $88.23M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $21.91M 10-Q · filed 2024-05-02 | $43.70M derived: sum of 2 quarters · filed 2025-02-20 | $61.06M derived: sum of 3 quarters · filed 2025-02-20 | $89.34M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $21.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $39.15M derived: sum of 2 quarters · filed 2025-02-20 | $67.44M derived: sum of 3 quarters · filed 2025-02-20 | $91.56M 10-K · filed 2025-02-20 |
| 2022-09-30 | $17.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $45.65M derived: sum of 2 quarters · filed 2023-11-02 | $69.77M 10-Q · filed 2023-11-02 | $89.54M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $28.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $52.41M 10-Q · filed 2023-08-03 | $72.18M derived: sum of 3 quarters · filed 2024-02-22 | $88.22M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $24.12M 10-Q · filed 2023-05-04 | $43.90M derived: sum of 2 quarters · filed 2024-02-22 | $59.94M derived: sum of 3 quarters · filed 2024-02-22 | $90.05M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $19.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $35.82M derived: sum of 2 quarters · filed 2024-02-22 | $65.93M derived: sum of 3 quarters · filed 2024-02-22 | $99.50M 10-K · filed 2024-02-22 |
| 2021-09-30 | $16.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $46.15M derived: sum of 2 quarters · filed 2022-11-03 | $79.73M 10-Q · filed 2022-11-03 | $91.88M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $30.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $63.69M 10-Q · filed 2022-08-04 | $75.83M derived: sum of 3 quarters · filed 2023-02-23 | $93.53M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $33.58M 10-Q · filed 2022-05-05 | $45.72M derived: sum of 2 quarters · filed 2023-02-23 | $63.42M derived: sum of 3 quarters · filed 2023-02-23 | $81.81M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $12.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $29.84M derived: sum of 2 quarters · filed 2023-02-23 | $48.24M derived: sum of 3 quarters · filed 2023-02-23 | $58.46M 10-K · filed 2023-02-23 |
| 2020-09-30 | $17.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $36.09M derived: sum of 2 quarters · filed 2021-11-04 | $46.31M 10-Q · filed 2021-11-04 | $56.32M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $18.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $28.61M 10-Q · filed 2021-08-05 | $38.62M derived: sum of 3 quarters · filed 2022-02-25 | $44.40M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $10.22M 10-Q · filed 2021-05-06 | $20.23M derived: sum of 2 quarters · filed 2022-02-25 | $26.01M derived: sum of 3 quarters · filed 2022-02-25 | $29.36M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $10.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $15.78M derived: sum of 2 quarters · filed 2022-02-25 | $19.14M derived: sum of 3 quarters · filed 2022-02-25 | $21.37M 10-K · filed 2022-02-25 |
| 2019-09-30 | $5.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $9.13M derived: sum of 2 quarters · filed 2020-11-05 | $11.37M 10-Q · filed 2020-11-05 | $14.48M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $5.59M 10-Q · filed 2020-08-11 | $8.70M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $2.23M 10-Q · filed 2020-05-14 | $5.34M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $6.07M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $2.95M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $1.84M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |